Matthew S. Davids, MD, on Clinical Implications of New Data on Newer CLL Therapies

Posted: Tuesday, December 8, 2020

Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses overarching insights on newer therapies such as ibrutinib and venetoclax for chronic lymphocytic leukemia, how the different regimens apply to first-line vs the relapsed/refractory settings, and other clinical pearls from three pivotal studies.